HER2 Support Group Forums - View Single Post - Here it is: How her2+ breast cancer quickly becomes resistant to lapatinib unless ER

heblaj01 · 08-26-2006, 08:10 AM

Thanks,Lani,for posting this important article.
Based on various articles previously posted by several members it is possible that a similar process of resistance to Herceptin is also involving the so called crosstalk with ER.
This gives more support to the intuition expressed by Dr Pegram in an earlier interview where he implied that among the anti estrogen drugs Fulvestrant in combination with Herceptin might be the best choice since it suppresses the estrogen receptor rather than circulating estrogen thus leaving no possibility of crosstalk.
Nevertheless,judging from a small poll of members taking Herceptin plus one of the aromatase inhibitors (such as Femara, Arimidex etc...) good response was reported without the help of Fulvestrant.

The full report of the small phase 2 trial of Arimidex+Herceptin is supposed to be released by Roche at the end of september 2006 at a meeting of European
oncologists in Turkey.

08-26-2006, 08:10 AM	#2
heblaj01 Senior Member Join Date: Apr 2006 Posts: 543	Thanks,Lani,for posting this important article. Based on various articles previously posted by several members it is possible that a similar process of resistance to Herceptin is also involving the so called crosstalk with ER. This gives more support to the intuition expressed by Dr Pegram in an earlier interview where he implied that among the anti estrogen drugs Fulvestrant in combination with Herceptin might be the best choice since it suppresses the estrogen receptor rather than circulating estrogen thus leaving no possibility of crosstalk. Nevertheless,judging from a small poll of members taking Herceptin plus one of the aromatase inhibitors (such as Femara, Arimidex etc...) good response was reported without the help of Fulvestrant. The full report of the small phase 2 trial of Arimidex+Herceptin is supposed to be released by Roche at the end of september 2006 at a meeting of European oncologists in Turkey.